Sorrento Therapeutics Inc (SRNE)

[1776club]

It's darkest just before the lights go out...just kidding.
Company could be a $60-billion-dollar company with sales of $18 to 20 billion
How does that work?
(20B sales/500 million shares)*17%*(PE 15 to 25x)
So, I chose 20% yielding $136.share
500 million shares and you have a company of $68 Billion.

Due to Abivertinib finishing in 2024 due to, we deserve an explanation, FDA concerns causing a redo of P1 and P2 it may take longer than expected...but there are many things in the pipeline that could add revenue in...

ABIVERTINIB (treatment) Severe COVID-19 in ICU Patients 2023
Biological: Anti-CEA CAR-T cells 2023
Biological: COVI-DROPS 2022/2023
Biological: COVI-MSC 2022/2023
Drug: Abivertinib Maleate Capsules NSCLC 2024/2025

Let us not forget SCILEX in 2022 going public and revenue in 2023.
estimate SORRENTO 2023 sales of $4b, $20 - $40 stock and a $17B company.
Advance orders in 2022 could make the stock pop sooner.

COVISTIX and VIREX Health will add billions 2022/2023 and SOFUSA could add billions 2023/2025 with BP partnering.